Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$135.90 USD
-1.03 (-0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.97 +0.07 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Detailed Estimates
EPS Estimates
Earnings Date | *AMC5/2/24 |
---|---|
Current Quarter | -1.57 |
EPS Last Quarter | -1.66 |
Last EPS Surprise | 22.79% |
ABR | 1.46 |
Earnings ESP
|
13.61% |
---|---|
Current Year | -4.15 |
Next Year | -0.36 |
EPS (TTM) | -9.25 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 85.72M | 98.18M | 442.54M | 792.80M |
# of Estimates | 5 | 5 | 6 | 6 |
High Estimate | 101.71M | 107.96M | 529.22M | 879.99M |
Low Estimate | 77.00M | 89.93M | 401.46M | 682.48M |
Year ago Sales | 36.04M | 51.59M | 288.27M | 442.54M |
Year over Year Growth Est. | 137.85% | 90.30% | 53.51% | 79.15% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.57 | -1.36 | -4.15 | -0.36 |
# of Estimates | 7 | 5 | 8 | 7 |
Most Recent Consensus | -1.00 | -1.07 | -3.08 | 0.47 |
High Estimate | -1.00 | -1.07 | -2.75 | 1.87 |
Low Estimate | -1.94 | -1.64 | -5.89 | -2.35 |
Year ago EPS | -2.12 | -2.35 | -9.24 | -4.15 |
Year over Year Growth Est. | 25.94% | 42.13% | 55.09% | 91.25% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 2 | 0 | 1 | 2 |
Up Last 60 Days | 2 | 0 | 1 | 2 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 1 | 1 | 0 |
Down Last 60 Days | 0 | 1 | 1 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.57 | -1.36 | -4.15 | -0.36 |
7 Days Ago | -1.57 | -1.36 | -4.15 | -0.36 |
30 Days Ago | -1.58 | -1.33 | -4.16 | -0.42 |
60 Days Ago | -1.58 | -1.33 | -4.16 | -0.42 |
90 Days Ago | -2.10 | -1.97 | -5.69 | -2.05 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.36 | -1.11 | -3.76 | 0.86 |
Zacks Consensus Estimate | -1.57 | -1.36 | -4.15 | -0.36 |
Earnings ESP | 13.61% | 18.26% | 9.43% | 334.70% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -1.66 | -3.12 | -2.35 | -2.12 | NA |
Estimate | -2.15 | -2.63 | -2.68 | -2.84 | NA |
Difference | 0.49 | -0.49 | 0.33 | 0.72 | 0.26 |
Surprise | 22.79% | -18.63% | 12.31% | 25.35% | 10.46% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more